Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

HUMORAL IMMUNE RESPONSE AGAINST NON-TARGETED TUMOR ANTIGENS AFTER TREATMENT WITH SIPULEUCEL-T AND ITS ASSOCIATION WITH IMPROVED CLINICAL OUTCOME.

GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher T, Hall SJ, Kantoff P, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG.

Clin Cancer Res. 2015 Feb 3. pii: clincanres.2334.2014. [Epub ahead of print]

PMID:
25649018
2.

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju268. doi: 10.1093/jnci/dju268. Print 2014 Nov. Erratum in: J Natl Cancer Inst. 2014 Nov;106(11):dju372 doi:10.1093/jnci/dju372.

3.

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):259-64. doi: 10.1038/pcan.2014.21. Epub 2014 Jun 24.

4.

Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.

Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF.

Urology. 2013 Aug;82(2):410-5. doi: 10.1016/j.urology.2013.04.049.

PMID:
23896100
5.

Plant science and agricultural productivity: why are we hitting the yield ceiling?

de Bossoreille de Ribou S, Douam F, Hamant O, Frohlich MW, Negrutiu I.

Plant Sci. 2013 Sep;210:159-76. doi: 10.1016/j.plantsci.2013.05.010. Epub 2013 May 23. Review.

PMID:
23849123
6.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.

Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9.

PMID:
23582482
7.

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.

Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL.

Cancer Immunol Immunother. 2013 Jan;62(1):137-47. doi: 10.1007/s00262-012-1317-2. Epub 2012 Aug 3.

8.

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF.

J Natl Cancer Inst. 2012 Jul 18;104(14):1107-9; author reply 1109-12. doi: 10.1093/jnci/djs279. No abstract available.

9.

Sipuleucel-T for the treatment of advanced prostate cancer.

Frohlich MW.

Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004. Review.

PMID:
22595047
10.

'Living stones' reveal alternative petal identity programs within the core eudicots.

Brockington SF, Rudall PJ, Frohlich MW, Oppenheimer DG, Soltis PS, Soltis DE.

Plant J. 2012 Jan;69(2):193-203. doi: 10.1111/j.1365-313X.2011.04797.x. Epub 2011 Nov 23.

PMID:
21951031
11.

Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.

Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB.

J Urol. 2011 Sep;186(3):877-81. doi: 10.1016/j.juro.2011.04.070. Epub 2011 Jul 23.

PMID:
21788048
12.

Characterization of C₃--C₄ intermediate species in the genus Heliotropium L. (Boraginaceae): anatomy, ultrastructure and enzyme activity.

Muhaidat R, Sage TL, Frohlich MW, Dengler NG, Sage RF.

Plant Cell Environ. 2011 Oct;34(10):1723-36. doi: 10.1111/j.1365-3040.2011.02367.x. Epub 2011 Jul 5.

PMID:
21631534
13.

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.

Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW.

Clin Cancer Res. 2011 Jul 1;17(13):4558-67. doi: 10.1158/1078-0432.CCR-10-3223. Epub 2011 May 10.

14.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

15.

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.

Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW.

Clin Cancer Res. 2009 Sep 15;15(18):5937-44. doi: 10.1158/1078-0432.CCR-08-3282. Epub 2009 Sep 1.

16.
17.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.

18.

An easily built diffuse illumination system effective at both very low and moderate magnifications, for observing in situ stained slides.

Frohlich MW, Moyroud E.

J Microsc. 2008 Apr;230(Pt 1):160-2. doi: 10.1111/j.1365-2818.2008.01965.x.

PMID:
18387050
19.

Molecular evolution of PISTILLATA-like genes in the dogwood genus Cornus (Cornaceae).

Zhang W, Xiang QY, Thomas DT, Wiegmann BM, Frohlich MW, Soltis DE.

Mol Phylogenet Evol. 2008 Apr;47(1):175-95. doi: 10.1016/j.ympev.2007.12.022. Epub 2008 Jan 1.

PMID:
18304837
20.

After a dozen years of progress the origin of angiosperms is still a great mystery.

Frohlich MW, Chase MW.

Nature. 2007 Dec 20;450(7173):1184-9. Review.

PMID:
18097399
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk